From Dog

Docetaxel is an antimitotic chemotherapy drug used for treatment of certain cancers.

This drug, which is chemically related to paclitaxel, is usually administered as as adjunct drug in combination with doxorubicin or cyclosporine.

This drug has shown some antitumor responses in dogs with metastatic osteosarcoma, mammary adenocarcinoma (post-operative adjunct in combination with doxorubicin)[1] and malignant histiocytosis.

Anaphylaxis is less commonly reported compared with its sister drug, but premedication with daily prednisolone 2 - 3 days prior and diphenhydramine 30 - 60 minutes prior to and during docetaxel delivery.

Docetaxel has been used in combination with cyclosporine with some responses in dogs with oral squamous cell carcinoma[2].

Side-effects are often limited to a dose-related neutropenia and gastroenteritis[3].

Recommended dose rate in dogs is 20 - 30 mg/m2 given as an intravenous injection once every 2 - 3 weekly intervals.

An orally bio-available formulation has also been reportedly effective[4], with no anaphylactoid reactions[5].


  1. Simon D et al (2006) Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med 20(5):1184-1190
  2. Waite A et al (2012) Phase II study of oral docetaxel and cyclosporine in canine epithelial cancer. Vet Comp Oncol Aug 21
  3. McEntee M et al (2003) Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet Comp Oncol 1(2):105-112
  4. Li CM et al (2012) Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer. Pharm Res 29(11):3053-3063
  5. McEntee MC et al (2006) Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs. Am J Vet Res 67(6):1057-1062